In this review:
This review summarises the IMpower150 study, an open-label, phase III trial that evaluated Tecentriq® (atezolizumab) plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC) who had not previously received chemotherapy.1 The study concluded that the addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of programmed death ligand-1 (PD-L1) expression and EGFR or ALK genetic alteration status.
Download PDF